A phase 1a/1b, first-in-human study of a new immunotherapy agent, AB248, has given the agent to the first patient with a locally advanced or metastatic solid tumor. The first patient received a dose of a new therapy, AB248, as part of AB248-011 (NCT05653882) a phase 1a/1b study of immunotherapy in combination with pembrolizumab (Keytruda) for …
Prior treatment for newly diagnosed acute lymphoblastic leukemia (ALL) in adults has included multiple chemotherapy regimens for several decades, and has induced remission in most patients.1 Unfortunately, these remissions are usually not long-lasting, and many patients eventually relapse and require additional treatment.2-4 Since 2010, several new highly active therapies have been approved for relapsed ALL, …
New immunotherapy in the initial setting shows improved outcomes in ALL Read More »
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with a poor prognosis and limited treatment options. Researchers at Rutgers Cancer Institute of New Jersey, the state’s leading cancer program and the only National Cancer Institute-designated Comprehensive Cancer Center, along with RWJBarnabas Health, in collaboration with researchers at MD Anderson Cancer Center, have discovered a …